7 This presents the idea that GLP-1 RAs exert effects beyond weight loss or glycemic control, perhaps acting locally on immune cells or keratinocytes
M.DagenaisG
Saxenda: nausea, diarrhea, constipation, vomiting, injection site reactions, headache, low blood sugar, upset stomach, fatigue, dizziness, abdominal pain, increased lipase (a digestive enzyme), upper abdominal pain, fever, and gastroenteritis (inflammation of the stomach and intestines)
**Patients without diabetes and with BMI 30, or BMI 27 plus a weight-related condition, lost an average of 20% of their body weight by 1 year in a 72-week trial studying the highest maintenance dose of Zepbound (15 mg), when paired with diet and exercise changes (compared to 3% with diet and exercise alone)
"While GLP-1 medications affect gastrointestinal tract motility, their quantified impact may not be as significant as previously assumed, said corresponding author, Dr Walter Chan, director of the Center of Gastrointestinal Motility and a physician in the Brigham's Division of Gastroenterology, Hepatology and Endoscopy
